ENGLISH NEWS Special

OBESITY DRUG DEVELOPER BIOAGE LABS TARGETS $640M VALUATION IN UPSIZED US IPO

Mario Nawfal

@MarioNawfal
ЁЯЪиOBESITY DRUG DEVELOPER BIOAGE LABS TARGETS $640M VALUATION IN UPSIZED US IPO

The company plans to raise up to $199.5 million by offering 10.5 million shares priced between $17 to $19 each, up from an earlier plan of 7.5 million shares.

BioAge will list on Nasdaq under the symbol “BIOA”.

Source: Reuters